Meeting
2021 ASCO Annual Meeting
Natural history of patients (pts) with advanced cholangiocarcinoma (CCA) with FGFR2 gene fusion/rearrangement or wild-type (WT) FGFR2.
Authors
Rachna T. Shroff
University of Arizona Cancer Center, Tucson, AZ
Rachna T. Shroff , Jessica Rearden , Ai Li , Susan Moran , Stacie Peacock Shepherd , Angela Lamarca
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4089)
DOI
10.1200/JCO.2021.39.15_suppl.4089
Abstract #
4089
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Natural history of patients with advanced cholangiocarcinoma and FGFR2 gene fusions/rearrangements.
First Author: Rachna T. Shroff
Poster
2021 Gastrointestinal Cancers Symposium
Real-world data on overall survival associated with biweekly versus weekly cetuximab among metastatic colorectal cancer (mCRC) patients in the United States.
First Author: Himani Agg
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA).
First Author: Junji Furuse
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world use of pemigatinib (pemi) for cholangiocarcinoma (CCA) among racial and ethnic minorities in the United States.
First Author: Richard D. Kim